Vertex Pharmaceuticals (VRTX) On Guidance Upgrade And Pipeline Growth Narrative

Vertex Pharmaceuticals (VRTX) recently updated its full-year revenue guidance after strong Q2 2026 results and announced a new collaboration with AbCellera Biologics for autoimmune diseases. Despite a strong stock performance and a fresh bump to guidance, the company is considered undervalued with a fair value of $558.68 based on growth and margin assumptions, emphasizing pipeline diversification beyond cystic fibrosis. However, this valuation depends on successful execution and managing pricing pressures.